Werewolf Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| WEREWOLF THERAPEUTICS, INC. | ||
| Date: March 11, 2025 | By: | /s/ Daniel J. Hicklin |
|---|---|---|
| Daniel J. Hicklin, Ph.D. | ||
| President and Chief Executive Officer | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Daniel J. Hicklin | President, Chief Executive Officer and Director (Principal Executive Officer) | March 11, 2025 |
| Daniel J. Hicklin, Ph.D. | ||
| /s/ Timothy W. Trost | Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) | March 11, 2025 |
| Timothy W. Trost | ||
| /s/ Luke Evnin | Chair of the Board of Directors | March 11, 2025 |
| Luke Evnin, Ph.D. | ||
| /s/ Michael B. Atkins | Director | March 11, 2025 |
| Michael B. Atkins, M.D. | ||
| /s/ Meeta Chatterjee | Director | March 11, 2025 |
| Meeta Chatterjee, Ph.D. | ||
| /s/ Derek DiRocco | Director | March 11, 2025 |
| Derek DiRocco, Ph.D. | ||
| /s/ Alon Lazarus | Director | March 11, 2025 |
| Alon Lazarus, Ph.D. | ||
| /s/ Briggs W. Morrison | Director | March 11, 2025 |
| Briggs W. Morrison, M.D. | ||
| /s/ Michael A. Sherman | Director | March 11, 2025 |
| Michael A. Sherman, M.B.A. | ||
| /s/ Anil K. Singhal | Director | March 11, 2025 |
| Anil K. Singhal | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.